Surasarang Soraya Hengsawas, Sahakijpijarn Sawittree, Florova Galina, Komissarov Andrey A, Nelson Christina L, Perenlei Enkhbaatar, Fukuda Satoshi, Wolfson Marla R, Shaffer Thomas H, Idell Steven, Williams Robert O
The University of Texas at Austin, College of Pharmacy, Division of Molecular Pharmaceutics and Drug Delivery, Austin, TX, USA.
The University of Texas Health Science Center at Tyler, School of Medical Biological Sciences, Tyler, TX, USA.
J Drug Deliv Sci Technol. 2018 Aug;48:19-27. doi: 10.1016/j.jddst.2018.04.013. Epub 2018 Apr 30.
Single-chain tissue-type plasminogen activator (sctPA) and single-chain urokinase plasminogen activator (scuPA) have attracted interest as enzymes for the treatment of inhalational smoke-induced acute lung injury (ISALI). In this study, the pulmonary delivery of commercial human sctPA and lyophilized scuPA and their reconstituted solution forms were demonstrated using vibrating mesh nebulizers (Aeroneb® Pro (active) and EZ Breathe® (passive)). Both the Aeroneb® Pro and EZ Breathe® vibrating mesh nebulizers produced atomized droplets of protein solution of similar size of less than about 5 μm, which is appropriate for pulmonary delivery. Enzymatic activities of scuPA and of sctPA were determined after nebulization and both remained stable (88.0% and 93.9%). Additionally, the enzymatic activities of sctPA and tcuPA were not significantly affected by excipients, lyophilization or reconstitution conditions. The results of these studies support further development of inhaled formulations of fibrinolysins for delivery to the lungs following smoke-induced acute pulmonary injury.
单链组织型纤溶酶原激活剂(sctPA)和单链尿激酶型纤溶酶原激活剂(scuPA)作为治疗吸入烟雾所致急性肺损伤(ISALI)的酶引起了人们的关注。在本研究中,使用振动网孔雾化器(Aeroneb® Pro(主动式)和EZ Breathe®(被动式))证明了市售人sctPA和冻干scuPA及其重构溶液形式的肺部给药。Aeroneb® Pro和EZ Breathe®振动网孔雾化器均产生了大小相似、小于约5μm的蛋白质溶液雾化液滴,这适合肺部给药。雾化后测定了scuPA和sctPA的酶活性,两者均保持稳定(分别为88.0%和93.9%)。此外,sctPA和tcuPA的酶活性不受辅料、冻干或重构条件的显著影响。这些研究结果支持进一步开发纤维蛋白溶解素吸入制剂,用于烟雾诱导的急性肺损伤后肺部给药。